000			02062nam a22002897a 4500
003			OSt
005			20240305193737.0
008			221125b |||||||| |||| 00| 0 eng d
028			_b Phone: +255 28 298 3384
028			_b Fax: +255 28 298 3386
028			_bEmail: vc@bugando.ac.tz
028			_b Website: www.bugando.ac.tz
040			_bEnglish _cDLC
041			_aEnglish
100			_aDaniela Urrego _945996
245			_aCyclooxygenase inhibitors for treating preterm labour: What is the molecular evidence?
260			_aMwanza, Tanzania: _bNRC Research Press & _b Catholic University of Health and Allied Sciences [CUHAS – Bugando] _c 2019
300			_a Pages 222-231
490			_vCanadian Journal of Physiology and Pharmacology Volume 97 Issue 3
520			_aPreterm birth (<37 weeks of gestation) significantly increases the risk of neonatal mortality and morbidity. As many as half of all preterm births occur following spontaneous preterm labour. Since in such cases there are no known reasons for the initiation of labour, treatment of preterm labour (tocolysis) has sought to stop labour contractions and delay delivery. Despite some success, the use of cyclooxygenase (COX) inhibitors is associated with maternal/fetal side effects, and possibly increased risk of preterm birth. Clinical use of these drugs predates the collection of molecular and biochemical evidence in vitro, examining the expression and activity of COX enzymes in pregnant uterine tissues with and without labour. Such evidence is important to the rationale that COX enzymes are, or are not, appropriate targets for the tocolysis. The current study systematically searched existing scientific evidence to address the …
700			_aAnthony C Liwa _923052
700			_a William C Cole _945997
700			_a Stephen L Wood _945998
700			_aDonna M Slater _945999
856			_uhttps://scholar.google.com/citations?view_op=view_citation&hl=en&user=2C33oewAAAAJ&citation_for_view=2C33oewAAAAJ:roLk4NBRz8UC
942			_2ddc _cVM
999			_c19707 _d19707